Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers
about
Genomic analysis to guide choice of treatment for smoking cessationThe ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sexCYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropionPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesWhy We Must Continue to Investigate Menthol's Role in the African American Smoking Paradox.Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.Epidemiology, determinants, and consequences of cigarette smoking in African American women: an integrative review.Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite RatioEffects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in miceAssociation of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokersKnown and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokersGlucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphismsGenetic factors control nicotine self-administration in isogenic adolescent rat strains.Pathways to precision medicine in smoking cessation treatments.Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.Associations of CYP2A6 genotype with smoking behaviors in southern China.CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populationsVariation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.The health effects of menthol cigarettes as compared to non-menthol cigarettesClinically relevant genetic variations in drug metabolizing enzymes.Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS.Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.Smokescreen: a targeted genotyping array for addiction researchCYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native peopleNicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes.Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers.Reproducibility of the nicotine metabolite ratio in cigarette smokers.Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking SmokersHepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation.Dose-independent kinetics with low level exposure to nicotine and cotininePredictors of cessation in African American light smokers enrolled in a bupropion clinical trialNicotine intake and smoking topography in smokers with bipolar disorderNicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers
P2860
Q24188234-8781BDD8-2FE4-43D3-9921-ACCA6980A228Q24595571-1A54FA77-DF99-4449-A9DD-5CFC0C8C1AF1Q24634660-3153BB80-B502-4593-9E0C-FAB692E584FFQ27012807-324F8423-8D73-4219-A0F6-F79E4333C0D6Q27023830-33EC1679-3EE1-4854-8618-1A860F9B5A75Q33362776-08CF23DE-9239-4C68-B9BF-F44D30CF685FQ33574895-42F4C541-3515-4DA5-9D0E-AF9393524F0EQ33693188-2E3FA963-D8BF-4F26-8420-8F3E235794BCQ33695828-4E1D804F-6277-47C3-8790-A9ABD9FEED06Q33803436-BB78B33A-D3E5-4723-A91D-64341F08A35EQ33821233-79FD4D46-AC78-496A-AA1C-A9B338D2B72FQ33933963-221A5C1F-33BD-458F-8F31-CB63D76CB600Q33953232-7C3FE4D7-EBC7-4636-B4ED-2D13E24DB506Q34135377-9703A5EB-FCD1-47F3-9988-853317A63192Q34390412-6A6B558A-38AB-4AA0-8BE3-133FA5F3F6BFQ34399720-920CADB7-2D23-4BAF-B268-47D8DF373C36Q34527740-F8F18317-A7A7-4432-9E15-54586D799FB0Q34632875-52143D41-2A45-434A-BCB5-BEB0488BAE50Q34778875-DA55E728-FAAA-48BD-BEB0-8635C307E8AEQ34918092-A0B7D1F0-F3A7-4176-98B3-545B29F0B63FQ34926339-828F99C5-79DD-4EFA-B9A1-5B093E8D8D7AQ35009983-514379CF-F20C-4DEB-B95A-C05A4EF627DFQ35032378-A5BA08EB-8963-4964-933C-93823FD5517BQ35099123-AAD6DE4E-A9E5-483B-AA55-F62AAD84D2D8Q35534291-4F98E19A-12F8-44E6-AC3A-335339A81433Q35751986-01270B8B-6B50-4A7C-B8E1-FC7419DE40E1Q35769015-D22A836B-22BD-4BEB-A835-D5F4900D183FQ35782141-BA802481-37DF-4B5E-AD2D-EE91953D9803Q35938102-5629FAE3-B8EE-4200-9D26-485BAD9AC937Q35949266-A116146D-0213-47CC-80A3-53E69B262D9EQ35974959-B5B8705A-9AC2-4B9E-9AEA-4F7085E1898FQ36021256-E46E14C8-A9E2-47D4-9C1D-099212C4C21EQ36084196-9E61855D-CDA6-4D4A-A757-556B1BE31794Q36303865-615EC272-A2F2-4206-B424-D0DED70F8822Q36459910-3ED65828-7CFE-4FA5-AA64-C2AB4E7010AFQ36499756-E9158C21-5C78-41A2-A470-8D77528A2FE8Q36562547-77FAD59F-711B-43C3-A7A7-D7D71EB2EE9FQ36572648-90C5CE67-8CD7-4DBC-8B42-B5FEF70A3BE8Q36810188-55DB6CC5-8063-472B-AC78-02586C1A59C1Q36870991-0C8F241B-A515-43E7-8B93-42E5953B1DE6
P2860
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Association of nicotine metabo ...... African-American light smokers
@en
type
label
Association of nicotine metabo ...... African-American light smokers
@en
prefLabel
Association of nicotine metabo ...... African-American light smokers
@en
P2093
P2860
P356
P1476
Association of nicotine metabo ...... African-American light smokers
@en
P2093
J C Mwenifumbo
J S Ahluwalia
K S Okuyemi
N Al Koudsi
N L Benowitz
P2860
P304
P356
10.1038/CLPT.2009.19
P407
P577
2009-03-11T00:00:00Z